Results 21 to 30 of about 116,093 (277)
Cholestasis can be caused by extrahepatic and intrahepatic pathogenic mechanisms that affect cellular and subcellular functions. The retention of bile results in numerous biochemical abnormalities, some of which are useful as clinical tests. The clinicopathologic findings are often suggestive of the underlying hepatobiliary disorder but are seldom ...
Associate Professor, Department of Medical Sciences, University of Florida College of Veterinary Medicine, Gainesville, FloridaDepartment of Medical SciencesUniversity of Florida College of Veterinary MedicineGainesvilleFlorida ( host institution ) +2 more
openaire +5 more sources
Hypercortisolism in patients with cholestasis is associated with disease severity
Background Cholestasis might lead to an impairment of adrenal function as suggested by in vitro and in vivo data as well as by clinical findings. Bile acid and adrenal steroid metabolism not only share the receptors farnesoid X receptor (FXR) and the G ...
Verena Theiler-Schwetz +6 more
doaj +1 more source
Progressive familial intrahepatic cholestasis
Neonatal cholestasis is one of the commonest presentations in the field of pediatric hepatol‐ ogy and gastroenterology and constitutes the major indication for liver transplantation be‐ low two years of age. Unfortunately, in spite of being common, fewer
R. Khanna, Vipul Gautam
semanticscholar +1 more source
Cholestasis is characterized by increased total bile acid (TBA) levels, which are regulated by farnesoid X receptor (FXR)/FGF15. Patients with primary sclerosing cholangitis (PSC) typically present with inflammatory bowel disease (IBD). Mast cells (MCs) (
Vik Meadows +13 more
semanticscholar +1 more source
Cholestatic jaundice is a common presenting feature of neonatal hepatobiliary and metabolic dysfunction. Any infant who remains jaundiced beyond age 2 to 3 weeks should have the serum bilirubin level fractionated into a conjugated (direct) and unconjugated (indirect) portion. Conjugated hyperbilirubinemia is never physiologic or normal.
Amy G, Feldman, Ronald J, Sokol
openaire +2 more sources
Background: Farnesoid X receptor (FXR) is a key metabolic target of bile acids (BAs) and is also a target for drugs against several liver diseases. However, the contribution of FXR in the pathogenesis of cholestasis is still not fully understood.
Shizhang Wei +8 more
doaj +1 more source
Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases [PDF]
In the past ten years, our understanding of the importance of bile acids has expanded from fat absorption and glucose/lipid/energy homeostasis into potential therapeutic targets for amelioration of chronic cholestatic liver diseases.
Alpini, Gianfranco +4 more
core +1 more source
In contrast with urine formation, bile flow is not dependent on hydrostatic forces, but driven by osmotic pressure of solutes secreted across the apical membrane of hepatocytes and bile duct epithelial cells. This secretory process is mediated by a set of primary active transporters that use ATP hydrolysis to pump solutes against the concentration ...
openaire +6 more sources
Intrahepatic cholestasis is the most common hepatobiliary complication of pregnancy. Worsening cholestasis, measured by total bile acid levels, has been associated with an increased incidence of adverse fetal outcomes; however, maternal morbidity remains
Minhazur Sarker +3 more
doaj +1 more source
Pharmacological interventions for treating intrahepatic cholestasis of pregnancy.
BACKGROUND Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder that can develop in pregnancy. It occurs when there is a build-up of bile acids in the maternal blood. It has been linked to adverse maternal and fetal/neonatal outcomes.
Kate F. Walker +4 more
semanticscholar +1 more source

